Metabolic stability, metabolite production, metabolic pathways & PPB of FHND6081 along with its absorption, tissue distribution, excretion & PK in animals.
/PRNewswire/ A2PG and Amador Bioscience announced today that Dr. Nidal Huniti has joined the company as President of A2PG. Dr. Huniti, a veteran of the.
2 Min Read
(Reuters) -U.S. drug development consultancy Certara Inc said on Thursday it sold shares in its initial public offering at $23 apiece, above its target range, to raise about $670 million.
The IPO valued Certara, which is owned by Stockholm-based private equity firm EQT, at $3.5 billion.
Certara said it sold 29.1 million shares after it had aimed to sell 24.4 million shares at a target price range of $19-$22 each.
The Princeton, New Jersey-based company was formed in 2008 after biotechnology firm Tripos International acquired Pharsight Corp. Certara provides pharmaceutical companies with computer-based drug trials using virtual patients rather than human beings - a technology known as “biosimulation.”